FLT3 and acute lymphoblastic leukemia: Because of FLT3 potential as a therapeutic target in childhood ALL, we tested the sensitivity of FLT3 mutants to Midostaurin, a type I FLT3 inhibitor that binds to the active form of the receptor, and Sorafenib, a type II inhibitor which interacts with the inactive conformation [30].